Equities

Egetis Therapeutics AB (publ)

Egetis Therapeutics AB (publ)

Actions
  • Price (SEK)5.61
  • Today's Change5.61 / --
  • Shares traded219.00
  • 1 Year change+28.67%
  • Beta--
Data delayed at least 20 minutes, as of Sep 09 2024 10:40 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow Back to Overview

In millions of SEK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
OPERATIONS
Net income(327)(194)(105)
Depreciation/depletion----2.46
Non-Cash items189.400.23
Cash taxes paid, supplemental0.100--
Cash interest paid, supplemental4.100.100.04
Changes in working capital3111(28)
Total cash from operations(278)(174)(130)
INVESTING
Capital expenditures00(0.17)
Other investing and cash flow items, total0(1.7)(5.79)
Total cash from investing0(1.7)(5.96)
FINANCING
Financing cash flow items(26)(13)0
Total cash dividends paid------
Issuance (retirement) of stock, net3821770
Issuance (retirement) of debt, net103(9.1)(8.9)
Total cash from financing459156(8.9)
NET CHANGE IN CASH
Foreign exchange effects(4.8)3.201.08
Net change in cash176(16)(144)
Net cash-begin balance/reserved for future use128144288
Net cash-end balance/reserved for future use303128144
SUPPLEMENTAL INCOME
Depreciation, supplemental----2.46
Cash interest paid, supplemental4.100.100.04
Cash taxes paid, supplemental0.100--
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.